Fatal Renal Bleeding in a Patient Treated With Aggressive Antithrombotic Therapy After Recurrent Coronary Stent Thrombosis
نویسندگان
چکیده
Triple antiplatelet therapy has been known to be superior to the conventional dual regimen for preventing stent thrombosis after coronary stenting, and the addition of oral anticoagulation to antiplatelet therapy is also considered an option. However, the risks and benefits of a triple antiplatelet regimen plus additional oral anticoagulation must be taken into account. Here, we report a case of fatal renal bleeding in a patient treated with triple antiplatelet plus oral anticoagulant therapy for the prevention of recurrent stent thrombosis.
منابع مشابه
Balancing Benefit and Bleeding Risk of Antithrombotic Agents in the Individual Patient With an Acute Coronary Syndrome
In most countries, the antithrombotic armamentarium for treating acute coronary syndrome (ACS) patients currently consists of aspirin, clopidogrel, heparin, enoxaparin, bivalirudin, and fondaparinux. A large number of new antithrombotic agents for treating ACS patients are about to enter the market or are under development: new P2Y12 inhibitors (prasugrel, ticagrelor, cangrelor), thrombin recep...
متن کاملBalancing benefit and bleeding risk of antithrombotic agents in the individual patient with an acute coronary syndrome.
In most countries, the antithrombotic armamentarium for treating acute coronary syndrome (ACS) patients currently consists of aspirin, clopidogrel, heparin, enoxaparin, bivalirudin, and fondaparinux. A large number of new antithrombotic agents for treating ACS patients are about to enter the market or are under development: new P2Y12 inhibitors (prasugrel, ticagrelor, cangrelor), thrombin recep...
متن کاملFatal bleedings with prasugrel as part of triple antithrombotic therapy.
Fatal Bleedings With Prasugrel as Part of Triple Antithrombotic Therapy Hemorragias mortales relacionadas con un tratamiento antitrombótico triple que incluye prasugrel To the Editor, Triple antithrombotic therapy with aspirin, clopidogrel, and warfarin is used in about 5% of patients after coronary stent implantation, mostly due to atrial fibrillation and left ventricular thrombosis. 1 This an...
متن کاملIndividualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
Dual antiplatelet therapy with aspirin and clopidogrel is currently the standard therapy after coronary stent implantation to prevent a life-threatening stent thrombosis. However, a variety of procedural and individual factors contribute to the individual patient risk and have to be taken into account to allow for an individual recommendation for both the duration and intensity of the antiplate...
متن کاملIschemic and Bleeding Risk in CAD Patients Requiring Surgery
Approximately 5% to 15% of patients undergoing coronary stent implantation are estimated to undergo a surgical procedure within 2 years. In the largest (N=126 773) cohort study to date describing the incidence and timing of noncardiac surgery after coronary stent placement, 12% of patients who received bare metal stents (BMSs) and 47% of patients who received drug-eluting stents (DESs) had earl...
متن کامل